$ALNY

Alnylam will present five-year data from the HELIOS-B Phase 3 study of AMVUTTRA (vutrisiran) at AHA and ISA 2026, showing long-term benefits in treating transthyretin amyloidosis (ATTR). The study includes open-label extension data and post hoc analyses demonstrating preserved exercise capacity and cardiopulmonary performance. Additional real-world evidence and comparisons with other treatments will also be presented.

Barclays kept Alnylam Pharmaceuticals at Overweight, cutting its price target to $380 from $450, a 15.6% reduction. This implies a 158.2% upside from the Oct 30 close of $147.17. Recent analyst targets for the company range from $199 to $354.

Truist Securities downgraded Alnylam Pharmaceuticals to Hold from Buy, reducing its price target to $225 from $315. This implies a 52.9% upside from the Oct 30 close of $147.17. Recent analyst price targets for the company range from $199 to $354.

Alnylam Pharmaceuticals (ALNY) stock fell 29.5% from October 15 to October 30, 2026, after reporting Q3 results and expressing dissatisfaction with demand growth. The stock has historically seen mixed performance post-drops, with shares higher in 4 of 9 cases a year later. ALNY reported $1.46B in Q3 revenue, up 16.7% YoY, with product revenues growing 52%. Management expects 2026 sales at the low end of its $4.2B-$4.5B range.

AstraZeneca (AZN) reiterated its $80B revenue target by 2030, announced a $1.5B cost-savings program, and shares rose 7%. Alnylam (ALNY) reported $1.13B Amvuttra revenue, but shares fell 20% due to concerns over Medicare reimbursement and insurer policies. Regeneron (REGN) saw shares rise 13% after reporting record sales for Dupixent, Eylea, and Libtayo, beating expectations.

Canaccord Genuity kept Alnylam Pharmaceuticals' rating at Buy but reduced its price target to $323 from $429, a 24.7% decrease. This implies a 119.5% upside from the Oct 30 close of $147.17. Recent analyst price targets for Alnylam range from $199 to $354.

The FDA is expected to decide on several drugs this month, including Capricor Therapeutics' Deramiocel, Regeneron and Alnylam's Cemdisiran, and Roche's Gazyva. Cemdisiran showed significant improvements in trials for generalized myasthenia gravis, while Gazyva met trial goals for primary membranous nephropathy. Roche's Giredestrant for breast cancer is also under review. Regeneron and Roche shares have risen this year, while Alnylam's have fallen.

UBS kept Alnylam Pharmaceuticals' rating at Buy but reduced its price target to $329 from $354, a 7.1% decrease. This implies a 99.4% upside from the Oct 30 close of $165. Recent analyst targets for the company range from $199 to $354.

TD Cowen kept its Buy rating on Alnylam Pharmaceuticals but cut its price target to $354 from $482, citing a 26.6% reduction. The new target suggests a 103.4% upside from the Oct 29 closing price of $174. Recent analyst price targets for the company range from $199 to $320.

Bernstein downgraded Alnylam Pharmaceuticals to Market Perform, lowering its price target to $199 from $376. The new target suggests a 14.4% upside from the Oct 29 close of $174. Recent analyst price targets for the company range from $220 to $320.